AR
Therapeutic Areas
R-Pharm Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Biosimilar Portfolio (e.g., rituximab, bevacizumab) | Oncology, Autoimmune Diseases | Phase 3 / Registration |
| Localized innovative oncology therapies (e.g., osimertinib) | Non-Small Cell Lung Cancer (NSCLC) | Commercial |
| Remdeform (remdesivir) | Viral Infections (COVID-19) | Commercial |
| Novel oncology agents | Oncology | Phase 1/Phase 2 |